| Year |
Citation |
Score |
| 2024 |
Wang AF, Hsueh B, Choi BD, Gerstner ER, Dunn GP. Immunotherapy for Brain Tumors: Where We Have Been, and Where Do We Go From Here? Current Treatment Options in Oncology. PMID 38649630 DOI: 10.1007/s11864-024-01200-9 |
0.324 |
|
| 2022 |
Bowman-Kirigin JA, Desai R, Saunders BT, Wang AZ, Schaettler MO, Liu CJ, Livingstone AJ, Kobayashi DK, Durai V, Kretzer NM, Zipfel GJ, Leuthardt EC, Osbun JW, Chicoine MR, Kim AH, ... ... Dunn GP, et al. The conventional dendritic cell 1 subset primes CD8+ T cells and traffics tumor antigen to drive anti-tumor immunity in the brain. Cancer Immunology Research. PMID 36409838 DOI: 10.1158/2326-6066.CIR-22-0098 |
0.302 |
|
| 2022 |
Dunn GP, Sherpa N, Manyanga J, Johanns TM. Considerations for personalized neoantigen vaccination in Malignant glioma. Advanced Drug Delivery Reviews. 186: 114312. PMID 35487282 DOI: 10.1016/j.addr.2022.114312 |
0.325 |
|
| 2021 |
Desai R, Coxon AT, Dunn GP. Therapeutic applications of the cancer immunoediting hypothesis. Seminars in Cancer Biology. PMID 33711414 DOI: 10.1016/j.semcancer.2021.03.002 |
0.383 |
|
| 2021 |
Mei Y, Bi WL, Agolia J, Hu C, Giantini Larsen AM, Meredith DM, Al Abdulmohsen S, Bale T, Dunn GP, Abedalthagafi M, Dunn IF. Immune profiling of pituitary tumors reveals variations in immune infiltration and checkpoint molecule expression. Pituitary. PMID 33492612 DOI: 10.1007/s11102-020-01114-3 |
0.307 |
|
| 2020 |
Chuntova P, Chow F, Watchmaker P, Galvez M, Heimberger AB, Newell EW, Diaz A, DePinho RA, Li MO, Wherry EJ, Mitchell D, Terabe M, Wainwright DA, Berzofsky JA, Herold-Mende C, ... ... Dunn GP, et al. Unique challenges for glioblastoma immunotherapy - Discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Neuro-Oncology. PMID 33367885 DOI: 10.1093/neuonc/noaa277 |
0.364 |
|
| 2020 |
Galati MA, Hodel KP, Gams MS, Sudhaman S, Bridge T, Zahurancik WJ, Ungerleider NA, Park VS, Ercan AB, Joksimovic L, Siddiqui I, Siddaway R, Edwards M, de Borja R, Elshaer D, ... ... Dunn GP, et al. Cancers from novel Pole mutant mouse models provide insights into polymerase-mediated hypermutagenesis and immune checkpoint blockade. Cancer Research. PMID 32938641 DOI: 10.1158/0008-5472.Can-20-0624 |
0.423 |
|
| 2020 |
Shah AS, Yahanda AT, Sylvester PT, Evans J, Dunn GP, Jensen RL, Honeycutt J, Cahill DP, Sutherland GR, Oswood M, Shah M, Abram SR, Rich KM, Dowling JL, Leuthardt EC, et al. Using Histopathology to Assess the Reliability of Intraoperative Magnetic Resonance Imaging in Guiding Additional Brain Tumor Resection: A Multicenter Study. Neurosurgery. PMID 32803226 DOI: 10.1093/Neuros/Nyaa338 |
0.307 |
|
| 2020 |
Uppaluri R, Campbell KM, Egloff AM, Zolkind P, Skidmore ZL, Nussenbaum B, Paniello RC, Rich JT, Jackson R, Pipkorn P, Michel LS, Ley J, Oppelt P, Dunn GP, Barnell EK, et al. Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase 2 Trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32665297 DOI: 10.1158/1078-0432.Ccr-20-1695 |
0.316 |
|
| 2020 |
Medikonda R, Dunn G, Rahman M, Fecci P, Lim M. A review of glioblastoma immunotherapy. Journal of Neuro-Oncology. PMID 32253714 DOI: 10.1007/S11060-020-03448-1 |
0.396 |
|
| 2020 |
Patel B, Taiwo R, Kim AH, Dunn GP. , a promoter of CNS malignancies. Neuro-Oncology Advances. 2: vdaa025. PMID 32226942 DOI: 10.1093/noajnl/vdaa025 |
0.307 |
|
| 2019 |
Johanns TM, Miller CA, Liu CJ, Perrin RJ, Bender D, Kobayashi DK, Campian JL, Chicoine MR, Dacey RG, Huang J, Fritsch EF, Gillanders WE, Artyomov MN, Mardis ER, Schreiber RD, ... Dunn GP, et al. Detection of neoantigen-specific T cells following a personalized vaccine in a patient with glioblastoma. Oncoimmunology. 8: e1561106. PMID 30906654 DOI: 10.1080/2162402X.2018.1561106 |
0.492 |
|
| 2019 |
Reardon DA, Kaley TJ, Dietrich J, Clarke JL, Dunn G, Lim M, Cloughesy TF, Gan HK, Park AJ, Schwarzenberger P, Ricciardi T, Macri MJ, Ryan A, Venhaus RR. Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) + radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM). Journal of Clinical Oncology. 37: 2032-2032. DOI: 10.1200/Jco.2019.37.15_Suppl.2032 |
0.314 |
|
| 2019 |
Liu C, Schaettler M, Bowman-Kirigin J, Bender D, Kobayashi DK, Miller CA, Johanns TM, Dunn GP. Combination Immune Treatment of a Highly Aggressive Orthotopic Murine Glioblastoma With Checkpoint Blockade Inhibition and Neoantigen Vaccination Neurosurgery. 66. DOI: 10.1093/Neuros/Nyz310_153 |
0.341 |
|
| 2019 |
Liu C, Schaettler M, Bowman-Kirigin J, Kobayashi D, Miller C, Johanns T, Dunn G. IMMU-09. COMBINATION IMMUNE TREATMENT OF A HIGHLY AGGRESSIVE ORTHOTOPIC MURINE GLIOBLASTOMA WITH CHECKPOINT BLOCKADE AND MULTI-VALENT NEOANTIGEN VACCINATION Neuro-Oncology. 21: vi120-vi121. DOI: 10.1093/Neuonc/Noz175.503 |
0.388 |
|
| 2019 |
Bouffet E, Sudhaman S, Chung J, Campbell B, Kelly J, Coblentz A, Edwards M, Lipman T, Zhang C, Ercan AB, Sambira L, Bendel A, Bielack S, Koustenis E, Blumenthal D, ... ... Dunn G, et al. IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL REPLICATION REPAIR DEFICIENCY CONSORTIUM Neuro-Oncology. 21: ii96-ii97. DOI: 10.1093/Neuonc/Noz036.139 |
0.388 |
|
| 2018 |
Zolkind P, Przybylski D, Marjanovic N, Nguyen L, Lin T, Johanns T, Alexandrov A, Zhou L, Allen CT, Miceli AP, Schreiber RD, Artyomov M, Dunn GP, Uppaluri R. Cancer immunogenomic approach to neoantigen discovery in a checkpoint blockade responsive murine model of oral cavity squamous cell carcinoma. Oncotarget. 9: 4109-4119. PMID 29423108 DOI: 10.18632/Oncotarget.23751 |
0.539 |
|
| 2017 |
Johanns TM, Bowman-Kirigin JA, Liu C, Dunn GP. Targeting Neoantigens in Glioblastoma: An Overview of Cancer Immunogenomics and Translational Implications. Neurosurgery. 64: 165-176. PMID 28899059 DOI: 10.1093/Neuros/Nyx321 |
0.381 |
|
| 2017 |
Mei Y, Bi WL, Greenwald NF, Agar NY, Beroukhim R, Dunn GP, Dunn IF. Genomic profile of human meningioma cell lines. Plos One. 12: e0178322. PMID 28552950 DOI: 10.1371/Journal.Pone.0178322 |
0.324 |
|
| 2017 |
Johanns TM, Dunn GP. Applied Cancer Immunogenomics: Leveraging Neoantigen Discovery in Glioblastoma. Cancer Journal (Sudbury, Mass.). 23: 125-130. PMID 28410300 DOI: 10.1097/Ppo.0000000000000247 |
0.401 |
|
| 2017 |
Uppaluri R, Zolkind P, Lin T, Nussenbaum B, Jackson RS, Rich J, Pipkorn P, Paniello R, Thorstad W, Michel L, Mudianto T, Oppelt PJ, Wildes TM, Dunn GP, Piccirillo JF, et al. Neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV negative head and neck squamous cell carcinoma (HNSCC). Journal of Clinical Oncology. 35: 6012-6012. DOI: 10.1200/Jco.2017.35.15_Suppl.6012 |
0.348 |
|
| 2017 |
Zolkind PA, Campbell KM, Lin T, Skidmore Z, Winkler A, Barnell E, Giri T, Adkins DR, Griffith M, Dunn GP, Griffith OL, Uppaluri R. Abstract PR01: Genomic and functional correlates from a phase II clinical trial of trametinib in surgically resectable oral cavity squamous cell carcinoma Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Aacrahns17-Pr01 |
0.382 |
|
| 2016 |
Uppaluri R, Winkler AE, Lin T, Law JH, Haughey BH, Nussenbaum B, Paniello RC, Rich JT, Diaz JA, Michel LS, Wildes T, Dunn GP, Zolkind P, Kallogjeri D, Piccirillo JF, et al. Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window of Opportunity Clinical Trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28151720 DOI: 10.1158/1078-0432.Ccr-16-1469 |
0.319 |
|
| 2016 |
Johanns TM, Ward JP, Miller CA, Wilson C, Kobayashi DK, Bender D, Fu Y, Alexandrov A, Mardis ER, Artyomov MN, Schreiber RD, Dunn GP. Endogenous Neoantigen-specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach. Cancer Immunology Research. PMID 27799140 DOI: 10.1158/2326-6066.Cir-16-0156 |
0.588 |
|
| 2016 |
Zolkind P, Dunn GP, Lin T, Griffith M, Griffith OL, Uppaluri R. Neoantigens in immunotherapy and personalized vaccines: Implications for head and neck squamous cell carcinoma. Oral Oncology. PMID 27751760 DOI: 10.1016/J.Oraloncology.2016.09.010 |
0.51 |
|
| 2016 |
Mei Y, Bi WL, Greenwald NF, Du Z, Agar NY, Kaiser UB, Woodmansee WW, Reardon DA, Freeman GJ, Fecci PE, Laws ER, Santagata S, Dunn GP, Dunn IF. Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. Oncotarget. PMID 27655724 DOI: 10.18632/Oncotarget.12088 |
0.341 |
|
| 2016 |
Johanns TM, Ward J, Wilson C, Kobayashi DK, Bender D, Fu Y, Alexandrov A, Artyomov MN, Miller CA, Mardis ER, Dunn GP. 143 Identification of Neoantigen-specific CD8+ T Cells in Two Murine Orthotopic Glioblastoma Models Using Cancer Immunogenomics. Neurosurgery. 63: 158. PMID 27399422 DOI: 10.1227/01.Neu.0000489713.52326.9A |
0.336 |
|
| 2016 |
Johanns TM, Fu Y, Kobayashi DK, Mei Y, Dunn IF, Mao DD, Kim AH, Dunn GP. High incidence of TERT mutation in brain tumor cell lines. Brain Tumor Pathology. PMID 26960334 DOI: 10.1007/S10014-016-0257-5 |
0.347 |
|
| 2016 |
Uppaluri R, Zolkind P, Lin T, Nussenbaum B, Paniello R, Rich J, Jackson R, Thorstad W, Gay HA, Daly M, Kallogjeri D, Dunn GP, Wildes TM, Michel LS, Chernock R, et al. Immunotherapy with pembrolizumab in surgically resectable head and neck squamous cell carcinoma. Journal of Clinical Oncology. 34: TPS6110-TPS6110. DOI: 10.1200/Jco.2016.34.15_Suppl.Tps6110 |
0.302 |
|
| 2016 |
Reardon DA, Dietrich J, Kaley T, Gan H, Dunn GP, Cloughesy T, Lim M, Clarke J, Park A, Pan L, Lai DW, Karakunnel J, Robbins P, Narwal R, Venhaus R. Abstract A046: Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 in patients with glioblastoma (GBM) Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-A046 |
0.318 |
|
| 2016 |
Doberstein K, Karst A, Etemadmoghadam D, Jones P, Dunn G, Hahn W, Bowtell D, Drapkin R. Abstract PR05: Identifying potential targets in Cyclin E-amplified tumors. Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Ovca15-Pr05 |
0.387 |
|
| 2016 |
Uppaluri R, Winkler A, Lin T, Law J, Haughey B, Nussenbaum B, Paniello R, Rich J, Diaz J, Michel L, Wildes T, Dunn G, Kallogjeri D, Zolkind P, Dehdashti F, et al. Abstract CT070: Biomarker and clinical response of oral cavity squamous cell carcinoma to the MEK 1/2 inhibitor trametinib: A phase II neoadjuvant window of opportunity clinical trial Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Ct070 |
0.324 |
|
| 2015 |
Dunn GP, Okada H. Principles of immunology and its nuances in the central nervous system. Neuro-Oncology. 17: vii3-vii8. PMID 26516224 DOI: 10.1093/Neuonc/Nov175 |
0.447 |
|
| 2015 |
Mao DD, Gujar AD, Mahlokozera T, Chen I, Pan Y, Luo J, Brost T, Thompson EA, Turski A, Leuthardt EC, Dunn GP, Chicoine MR, Rich KM, Dowling JL, Zipfel GJ, et al. A CDC20-APC/SOX2 Signaling Axis Regulates Human Glioblastoma Stem-like Cells. Cell Reports. 11: 1809-21. PMID 26074073 DOI: 10.1016/J.Celrep.2015.05.027 |
0.356 |
|
| 2015 |
Luo LY, Kim E, Cheung HW, Weir BA, Dunn GP, Shen RR, Hahn WC. The Tyrosine Kinase Adaptor Protein FRS2 Is Oncogenic and Amplified in High-Grade Serous Ovarian Cancer. Molecular Cancer Research : McR. 13: 502-9. PMID 25368431 DOI: 10.1158/1541-7786.Mcr-14-0407 |
0.416 |
|
| 2014 |
Aum DJ, Kim DH, Beaumont TL, Leuthardt EC, Dunn GP, Kim AH. Molecular and cellular heterogeneity: the hallmark of glioblastoma. Neurosurgical Focus. 37: E11. PMID 25434380 DOI: 10.3171/2014.9.Focus14521 |
0.43 |
|
| 2014 |
Woodworth GF, Dunn GP, Nance EA, Hanes J, Brem H. Emerging insights into barriers to effective brain tumor therapeutics. Frontiers in Oncology. 4: 126. PMID 25101239 DOI: 10.3389/Fonc.2014.00126 |
0.344 |
|
| 2014 |
Onken MD, Winkler AE, Kanchi KL, Chalivendra V, Law JH, Rickert CG, Kallogjeri D, Judd NP, Dunn GP, Piccirillo JF, Lewis JS, Mardis ER, Uppaluri R. A surprising cross-species conservation in the genomic landscape of mouse and human oral cancer identifies a transcriptional signature predicting metastatic disease. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 2873-84. PMID 24668645 DOI: 10.1158/1078-0432.Ccr-14-0205 |
0.678 |
|
| 2014 |
Dunn GP, Cheung HW, Agarwalla PK, Thomas S, Zektser Y, Karst AM, Boehm JS, Weir BA, Berlin AM, Zou L, Getz G, Liu JF, Hirsch M, Vazquez F, Root DE, et al. In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene. Proceedings of the National Academy of Sciences of the United States of America. 111: 1102-7. PMID 24385586 DOI: 10.1073/Pnas.1311909111 |
0.423 |
|
| 2013 |
Jones PS, Dunn GP, Barker FG, Curry WT, Hochberg FH, Cahill DP. Molecular genetics of low-grade gliomas: genomic alterations guiding diagnosis and therapeutic intervention. 11th annual Frye-Halloran Brain Tumor Symposium. Neurosurgical Focus. 34: E9. PMID 23373454 DOI: 10.3171/2012.12.Focus12349 |
0.309 |
|
| 2013 |
Dunn GP, Andronesi OC, Cahill DP. From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma. Neurosurgical Focus. 34: E2. PMID 23373447 DOI: 10.3171/2012.12.Focus12355 |
0.331 |
|
| 2013 |
Allen CT, Law JH, Dunn GP, Uppaluri R. Emerging insights into head and neck cancer metastasis. Head & Neck. 35: 1669-78. PMID 23280716 DOI: 10.1002/Hed.23202 |
0.384 |
|
| 2013 |
Dunn GP, Spiliopoulos K, Plotkin SR, Hornicek FJ, Harmon DC, Delaney TF, Williams Z. Role of resection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis type 1. Journal of Neurosurgery. 118: 142-8. PMID 23101443 DOI: 10.3171/2012.9.Jns101610 |
0.332 |
|
| 2012 |
Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, Dunn IF, Agarwalla PK, Chheda MG, Campos B, Wang A, Brennan C, Ligon KL, Furnari F, Cavenee WK, Depinho RA, et al. Emerging insights into the molecular and cellular basis of glioblastoma. Genes & Development. 26: 756-84. PMID 22508724 DOI: 10.1101/Gad.187922.112 |
0.313 |
|
| 2012 |
Dunn GP, Fecci PE, Curry WT. Cancer immunoediting in malignant glioma. Neurosurgery. 71: 201-22; discussion 2. PMID 22353795 DOI: 10.1227/Neu.0B013E31824F840D |
0.512 |
|
| 2012 |
Judd NP, Winkler AE, Murillo-Sauca O, Brotman JJ, Law JH, Lewis JS, Dunn GP, Bui JD, Sunwoo JB, Uppaluri R. ERK1/2 regulation of CD44 modulates oral cancer aggressiveness. Cancer Research. 72: 365-74. PMID 22086849 DOI: 10.1158/0008-5472.Can-11-1831 |
0.354 |
|
| 2011 |
Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, Lee H, Arthur CD, White JM, Kalinke U, Murphy KM, Schreiber RD. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. The Journal of Experimental Medicine. 208: 1989-2003. PMID 21930769 DOI: 10.1084/Jem.20101158 |
0.713 |
|
| 2011 |
O'Sullivan T, Dunn GP, Lacoursiere DY, Schreiber RD, Bui JD. Cancer immunoediting of the NK group 2D ligand H60a. Journal of Immunology (Baltimore, Md. : 1950). 187: 3538-45. PMID 21876033 DOI: 10.4049/Jimmunol.1100413 |
0.576 |
|
| 2010 |
Wiedemeyer WR, Dunn IF, Quayle SN, Zhang J, Chheda MG, Dunn GP, Zhuang L, Rosenbluh J, Chen S, Xiao Y, Shapiro GI, Hahn WC, Chin L. Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM. Proceedings of the National Academy of Sciences of the United States of America. 107: 11501-6. PMID 20534551 DOI: 10.1073/Pnas.1001613107 |
0.36 |
|
| 2009 |
Refai D, Dunn GP, Santiago P. Giant cell tumor of the thoracic spine: case report and review of the literature. Surgical Neurology. 71: 228-33; discussion 2. PMID 18207522 DOI: 10.1016/J.Surneu.2007.07.056 |
0.363 |
|
| 2008 |
Uppaluri R, Dunn GP, Lewis JS. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers. Cancer Immunity. 8: 16. PMID 19053167 |
0.362 |
|
| 2008 |
Dunn GP, Lewis JS, Sunwoo JB, Uppaluri R. Spontaneous regression of cutaneous head and neck melanoma: implications for the immunologic control of neoplasia. Head & Neck. 30: 267-72. PMID 17657794 DOI: 10.1002/Hed.20701 |
0.334 |
|
| 2007 |
Dunn GP, Dunn IF, Curry WT. Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human glioma. Cancer Immunity. 7: 12. PMID 17691714 |
0.415 |
|
| 2006 |
Sheehan KC, Lai KS, Dunn GP, Bruce AT, Diamond MS, Heutel JD, Dungo-Arthur C, Carrero JA, White JM, Hertzog PJ, Schreiber RD. Blocking monoclonal antibodies specific for mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection. Journal of Interferon & Cytokine Research : the Official Journal of the International Society For Interferon and Cytokine Research. 26: 804-19. PMID 17115899 DOI: 10.1089/Jir.2006.26.804 |
0.772 |
|
| 2006 |
Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nature Reviews. Immunology. 6: 836-48. PMID 17063185 DOI: 10.1038/Nri1961 |
0.781 |
|
| 2006 |
Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Advances in Immunology. 90: 1-50. PMID 16730260 DOI: 10.1016/S0065-2776(06)90001-7 |
0.656 |
|
| 2005 |
Dunn GP, Ikeda H, Bruce AT, Koebel C, Uppaluri R, Bui J, Chan R, Diamond M, White JM, Sheehan KC, Schreiber RD. Interferon-gamma and cancer immunoediting. Immunologic Research. 32: 231-45. PMID 16106075 DOI: 10.1385/Ir:32:1-3:231 |
0.756 |
|
| 2005 |
Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, Bui JD, Diamond MS, Koebel CM, Arthur C, White JM, Schreiber RD. A critical function for type I interferons in cancer immunoediting. Nature Immunology. 6: 722-9. PMID 15951814 DOI: 10.1038/Ni1213 |
0.721 |
|
| 2005 |
Dunn GP, Sheehan KC, Old LJ, Schreiber RD. IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. Cancer Research. 65: 3447-53. PMID 15833880 DOI: 10.1158/0008-5472.Can-04-4316 |
0.591 |
|
| 2005 |
Dunn GP, Bruce AT, Sheehan KCF, Shankaran V, Uppaluri R, Bui JD, Diamond MS, Koebel CM, Arthur C, White JM, Schreiber RD. Erratum: Corrigendum: A critical function for type I interferons in cancer immunoediting Nature Immunology. 6: 852-852. DOI: 10.1038/Ni0805-852B |
0.684 |
|
| 2004 |
Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 21: 137-48. PMID 15308095 DOI: 10.1016/J.Immuni.2004.07.017 |
0.62 |
|
| 2004 |
Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annual Review of Immunology. 22: 329-60. PMID 15032581 DOI: 10.1146/Annurev.Immunol.22.012703.104803 |
0.66 |
|
| 2003 |
Popkin DL, Watson MA, Karaskov E, Dunn GP, Bremner R, Virgin HW. Murine cytomegalovirus paralyzes macrophages by blocking IFN gamma-induced promoter assembly. Proceedings of the National Academy of Sciences of the United States of America. 100: 14309-14. PMID 14614150 DOI: 10.1073/Pnas.1835673100 |
0.318 |
|
| 2002 |
Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunology. 3: 991-8. PMID 12407406 DOI: 10.1038/Ni1102-991 |
0.794 |
|
| Show low-probability matches. |